Claims for Patent: 9,828,373
✉ Email this page to a colleague
Summary for Patent: 9,828,373
Title: | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof |
Abstract: | The invention provides compounds as CDK small-molecule inhibitors and uses thereof, the compounds can be used for treating inflammation and cell proliferation diseases. The novel compound of the invention is a powerful cyclin-dependent kinase 4 (CDK 4) or cyclin-dependent kinase-6 (CDK 6) inhibitor. |
Inventor(s): | Liu; Bing (Dongguan, CN), Zhang; Yingjun (Dongguan, CN), Nie; Linlin (Dongguan, CN), Bai; Shun (Dongguan, CN), Guan; Mingyu (Dongguan, CN), Li; Xuke (Dongguan, CN), Cheng; Changchung (Dongguan, CN) |
Assignee: | SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) |
Application Number: | 15/318,366 |
Patent Claims: | 1. A compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, ##STR00125## wherein L is a
bond, --(C(R.sup.3b).sub.2).sub.n--, --N(R.sup.1)--(C(R.sup.3b).sub.2).sub.n--, --O--(C(R.sup.3b).sub.2).sub.n--, --S(.dbd.O).sub.m-- or --C(.dbd.O)--(C(R.sup.3b).sub.2).sub.n--; ring A is ##STR00126## and wherein when is a double bond, T is X,
##STR00127## when is a single bond, T is X.sup.6, ##STR00128## R is H, R.sup.13, --(C(R.sup.3b).sub.2).sub.n--N(R.sup.1a)--C(.dbd.O)--(C(R.sup.3b).sub.2).- sub.n--R.sup.13 or --(CH.sub.2).sub.n--C(.dbd.O)--N(R.sup.1a)--(C(R.sup.3b).sub.2).sub.n--R.-
sup.13; R.sup.13 is H, C.sub.3-9 cycloalkyl, heteroaryl, heterocyclyl, spiro heterobicyclyl, bridged heterobicyclyl or fused heterobicyclyl; each X.sup.7, X.sup.5 and X.sup.6 is independently --C(R.sup.3a).sub.2--, --N(R.sup.2)--, --O--,
--S(.dbd.O).sub.m-- or --C(.dbd.O)--; each X, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 is independently CR.sup.3a or N; each n is independently 0, 1, 2, 3, or 4; each n1 is independently 1, 2, or 3; each m is independently 0, 1, or 2; each R.sup.1a,
R.sup.1 and R.sup.2 is independently H, C.sub.1-4 haloalkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, (R.sup.4).sub.2N--(C(R.sup.3).sub.2).sub.n--, HO--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, N(R.sup.4).sub.2--C(.dbd.O)--,
HO--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--,
CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--, heterocyclyl, heteroaryl, C.sub.3-9 cycloalkyl or C.sub.1-4 alkyl; each R.sup.3a, R.sup.3b and R.sup.3 is independently H, F,
Cl, Br, C.sub.1-4 alkyl, hydroxy, carboxy, amino, heterocyclyl, heteroaryl, C.sub.3-9 cycloalkyl, C.sub.1-4 haloalkyl, H--(CH.sub.2).sub.n--O--(CH.sub.2).sub.n--, N(R.sup.4).sub.2--C(.dbd.O)--, H--(CH.sub.2).sub.n--SO.sub.2--(CH.sub.2).sub.n--,
H--O--(CH.sub.2).sub.n--C(.dbd.O)--(CH.sub.2).sub.n--, H--(CH.sub.2).sub.n--C(.dbd.O)--(CH.sub.2).sub.n-- or N(R.sup.4).sub.2--(CH.sub.2).sub.n--; each R.sup.4 is independently H, C.sub.1-4 alkyl, hydroxy, carboxy, amino, C.sub.1-4 alkoxy,
amino-C.sub.1-4-alkyl, NH.sub.2--C(.dbd.O)--, heterocyclyl, heteroaryl, C.sub.3-9 cycloalkyl, C.sub.1-4 haloalkyl or C.sub.1-4 alkylamino; each moiety represented by A is independently and optionally substituted with one, two, three or four substituents
independently selected from H, C.sub.1-4 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 alkylamino, amino-C.sub.1-4-alkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--,
(R.sup.4).sub.2N--(C(R.sup.3).sub.2).sub.n--, HO--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, N(R.sup.4).sub.2--C(.dbd.O)--, HO--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--,
H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).-
sub.n--, cyano and nitro; each alkyl, haloalkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, N(R.sup.4).sub.2--C(.dbd.O)--, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--,
--(C(R.sup.3).sub.2).sub.n--N(R.sup.4).sub.2, HO--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, HO--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--,
CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, spiro heterobicyclyl, bridged heterobicyclyl, fused heterobicyclyl, heterocyclyl, cycloalkyl, heteroaryl and H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n-- described in R,
R.sup.1, R.sup.1a, R.sup.2 and/or R.sup.13 is optionally and independently substituted with one, two, three or four independent R.sup.5; each R.sup.5 is independently H, oxo, C.sub.1-6 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C.sub.1-4 alkoxy,
C.sub.1-4 alkylamino, amino-C.sub.1-4-alkyl, N(R.sup.4).sub.2--C(.dbd.O)--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, C.sub.1-6 haloalkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--,
H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n-- -, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n1--C(.dbd.O)--(C(- R.sup.3).sub.2).sub.n--,
H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, cyano, heterocyclyl, C.sub.3-9 cycloalkyl, heteroaryl or nitro; each alkyl, alkoxy, alkylamino, aminoalkyl,
N(R.sup.4).sub.2--C(.dbd.O)--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, haloalkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--,
H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n-- -, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n1--C(.dbd.O)--(C(- R.sup.3).sub.2).sub.n--,
H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, heterocyclyl, cycloalkyl and heteroaryl described in R.sup.5 is independently and optionally substituted with one, two, three or four independent R.sup.6; and each R.sup.6 is independently H,
oxo, C.sub.1-4 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkylamino, amino-C.sub.1-4-alkyl, N(R.sup.4).sub.2--C(.dbd.O)--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, C.sub.1-4 haloalkyl,
H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n-- -,
H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n1--C(.dbd.O)--(C(- R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, cyano, heterocyclyl,
C.sub.3-9 cycloalkyl, heteroaryl or nitro, wherein each of heteroaryl, heterocyclyl, spiro heterobicyclyl, bridged heterobicyclyl and fused heterobicyclyl has 1-3 ring members independently selected from N, O, P and S, wherein heteroaryl is 5-6 membered
monocyclic ring, 7-10 membered bicyclic ring or 10-15 membered tricyclic ring; and wherein heterocyclyl is a saturated or partially unsaturated monocyclic ring having 3-7 ring members or a bicyclic ring having 7-10 ring members.
2. The compound of claim 1 having Formula (II) or Formula (III) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, ##STR00129## wherein L is a bond, --(CH.sub.2).sub.n--, --N(R.sup.1)--, --O--, --S-- or --C(.dbd.O)--. 3. The compound of claim 1, wherein R.sup.13 is H, ##STR00130## and wherein each Y, Y.sup.1, Y.sup.7 and Y.sup.2 is independently --C(R.sup.3c).sub.2--, --N(R.sup.2b)--, --O--, --S(.dbd.O).sub.m-- or --C(.dbd.O)--; each Y.sup.3, Y.sup.4 and Y.sup.5 is independently CR.sup.3c or N; and each R.sup.2b is independently H, C.sub.1-4 haloalkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, (R.sup.4).sub.2N--(C(R.sup.3).sub.2).sub.n--, HO--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, N(R.sup.4).sub.2--C(.dbd.O)--, HO--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n-- or C.sub.1-4 alkyl; each R.sup.3c is independently H, F, Cl, Br, C.sub.1-4 alkyl, hydroxy, carboxy, amino, C.sub.1-4 haloalkyl, H--(CH.sub.2).sub.n--O--(CH.sub.2).sub.n--, N(R.sup.4).sub.2--C(.dbd.O)--, H--(CH.sub.2).sub.n--SO.sub.2--(CH.sub.2).sub.n--, H--O--(CH.sub.2).sub.n--C(.dbd.O)--(CH.sub.2).sub.n--, H--(CH.sub.2).sub.n--C(.dbd.O)--(CH.sub.2).sub.n-- or N(R.sup.4).sub.2--(CH.sub.2).sub.n--; each e, r, f and g is independently 0, 1, 2, or 3. 4. The compound of claim 1, wherein R.sup.13 is cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, H, ##STR00131## ##STR00132## ##STR00133## and wherein each moiety represented by R.sup.13 is independently and optionally substituted with one, two, three or four independent R.sup.5. 5. The compound of claim 1, wherein ring A is ##STR00134## ##STR00135## ##STR00136## ##STR00137## each moiety represented by A is independently and optionally substituted with one, two, three or four substituents independently selected from H, C.sub.1-4 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 alkylamino, amino-C.sub.1-4-alkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, (R.sup.4).sub.2N--(C(R.sup.3).sub.2).sub.n--, HO--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, N(R.sup.4).sub.2--C(.dbd.O)--, HO--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--, cyano and nitro. 6. The compound of claim 1, wherein each R.sup.3a, R.sup.3b and R.sup.3 is independently H, F, Cl, Br, hydroxy, carboxy, amino, trifluoromethyl, methyl, ethyl, propyl, butyl, cyclopropyl, cyclohexyl, cyclopentyl, H--(CH.sub.2).sub.n--O--(CH.sub.2).sub.n--, N(R.sup.4).sub.2--C(.dbd.O)--, H--(CH.sub.2).sub.n--SO.sub.2--(CH.sub.2).sub.n--, H--O--(CH.sub.2).sub.n--C(.dbd.O)--(CH.sub.2).sub.n-- or N(R.sup.4).sub.2--(CH.sub.2).sub.n--; and each R.sup.4 is independently H, hydroxy, carboxy, amino, methoxy, aminomethyl, aminoethyl, NH.sub.2--C(.dbd.O)--, trifluoromethyl, 2,2-difluoroethyl, methyl, ethyl, propyl or butyl. 7. The compound of claim 1, wherein each R.sup.1a, R.sup.1 and R.sup.2 is independently H, 3,3,3-trifluoropropyl, trifluoromethyl, 1,1-difluoroethyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, (R.sup.4).sub.2N--(C(R.sup.3).sub.2).sub.n--, HO--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, N(R.sup.4).sub.2--C(.dbd.O)--, HO--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, CN--(C(R.sup.3).sub.2).sub.n--(C.dbd.O)--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--, ##STR00138## methyl, ethyl, propyl or butyl; each R.sup.5 is independently H, oxo, methyl, ethyl, propyl, butyl, F, Cl, Br, amino, hydroxy, carboxy, methoxy, C.sub.1-4 alkylamino, amino-C.sub.1-4-alkyl, N(R.sup.4).sub.2--C(.dbd.O)--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, ##STR00139## C.sub.1-4 haloalkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n-- -, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n1--C(.dbd.O)--(C(- R.sup.3).sub.2).sub.n--, cyano, cyclopropyl, cyclohexyl, cyclopentyl or nitro; and each R.sup.6 is independently H, oxo, methyl, ethyl, propyl, butyl, F, Cl, Br, amino, hydroxy, carboxy, methoxy, C.sub.1-4 alkylamino, amino-C.sub.1-4-alkyl, N(R.sup.4).sub.2--C(.dbd.O)--, CN--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--, C.sub.1-4 haloalkyl, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--C(.dbd.O)--C(.dbd.O)--(C(R.sup.3).sub.2).- sub.n--, H--(C(R.sup.3).sub.2).sub.n--C(.dbd.O)--(C(R.sup.3).sub.2).sub.n-- -, H--(C(R.sup.3).sub.2).sub.n--SO.sub.2--(C(R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n1--C(.dbd.O)--(C(- R.sup.3).sub.2).sub.n--, H--(C(R.sup.3).sub.2).sub.n--O--(C(R.sup.3).sub.2).sub.n--, cyano, heterocyclyl, C.sub.3-6 cycloalkyl or nitro. 8. The compound of claim 1 having one of the following structures: ##STR00140## ##STR00141## ##STR00142## ##STR00143## ##STR00144## ##STR00145## ##STR00146## ##STR00147## ##STR00148## ##STR00149## ##STR00150## ##STR00151## ##STR00152## ##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157## ##STR00158## ##STR00159## ##STR00160## ##STR00161## or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof. 9. A pharmaceutical composition comprising the compound of claim 1, and at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles. 10. The pharmaceutical composition of claim 9 further comprising an additional therapeutic agent; wherein the additional therapeutic agent is a chemotherapeutic drug, an antiproliferative agent, an immunosuppressor, an immunologic stimulant, an anti-inflammatory reagent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, a CDK4/6 inhibitor, an ABL inhibitor, an ABL/Scrinhibitor, an aurora kinase inhibitor, a non-ATP competitive inhibitor of BCR-ABL, a c-KIT mutation inhibitor, an RET inhibitor, a PDGFR inhibitor, a VEGFR inhibitor, a CSF1R inhibitor, an FLT3 inhibitor, an FLT3-ITD inhibitor or a combination thereof. 11. The pharmaceutical composition of claim 10, wherein the additional therapeutic agent is chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozotocin, cis-platinum, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbozine, methotrexate, fluorouracil, cytosine arabinoside, gemcitabine, purinethol, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, pharmorubicin, daunomycin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonadorelin analogue, megestrol acetate, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon .alpha., calcium folinate, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, zelboraf, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximab vedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, cabozantinib, ponatinib, midostaurin, pacritinib, quizartinib, gilteritinib, AKN-028, AT-9283, crenolanib, ENMD-2076, famitinib, dovitinib, PLX-3397, palbociclib, abemaciclib, ribociclib, rigosertib sodium, selinexor, roniciclib, AT-7519, seliciclib, alvocidib or a combination thereof. 12. A method of treating a disorder or disease in a human comprising administering a therapeutically effective amount of the compound of claim 1 to the human, wherein the disorder or disease is breast cancer caused by a change in cyclin-dependent kinase, wherein the cyclin-dependent kinase is CDK4 or CDK6. 13. A drug combination comprising the compound of claim 1 and one or more other activity agents used for treating proliferative diseases, autoimmune diseases or inflammatory diseases; wherein the other activity agent is a chemotherapeutic drug, an antiproliferative agent, an immunosuppressor, an immunologic stimulant, an anti-inflammatory agent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, a CDK 4/6 kinase inhibitor, an ABL inhibitor, an ABL/Scr inhibitor, an aurora kinase inhibitor, a non-ATP competitive inhibitor of BCR-ABL, a c-KIT mutation inhibitor, an RET inhibitor, a PDGFR inhibitor, a VEGFR inhibitor, a CSF1R inhibitor, a FLT3 inhibitor, a FLT3-ITD inhibitor or a combination thereof. 14. A method of treating a disorder or disease in a human comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 9 to the human, wherein the disorder or disease is breast cancer caused by a change in cyclin-dependent kinase, wherein the cyclin-dependent kinase is CDK4 or CDK6. 15. A drug combination comprising the pharmaceutical composition of claim 9 and one or more other activity agents used for treating proliferative diseases, autoimmune diseases or inflammatory diseases; wherein the other activity agent is a chemotherapeutic drug, an antiproliferative agent, an immunosuppressor, an immunologic stimulant, an anti-inflammatory agent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, a CDK 4/6 kinase inhibitor, an ABL inhibitor, an ABL/Scr inhibitor, an aurora kinase inhibitor, a non-ATP competitive inhibitor of BCR-ABL, a c-KIT mutation inhibitor, an RET inhibitor, a PDGFR inhibitor, a VEGFR inhibitor, a CSF1R inhibitor, a FLT3 inhibitor, a FLT3-ITD inhibitor or a combination thereof. |
Details for Patent 9,828,373
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2034-07-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2034-07-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2034-07-26 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2034-07-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.